Market revenue in 2023 | USD 1,051.1 million |
Market revenue in 2030 | USD 2,607.9 million |
Growth rate | 13.9% (CAGR from 2023 to 2030) |
Largest segment | Bioreactors/fermenters |
Fastest growing segment | Cell Culture Products |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioreactors/Fermenters, Cell Culture Products, Filters, Bioreactors Accessories, Bags & Containers |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Corning Inc, Sartorius AG, Eppendorf, Danaher Corp, Boehringer Ingelheim, Getinge AB Class B, Lonza Group Ltd, Avantor Inc, Repligen Corp, Entegris Inc, PBS Biotech, Meissner, Kuhner Shaker |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to upstream bioprocessing market will help companies and investors design strategic landscapes.
Bioreactors/fermenters was the largest segment with a revenue share of 31.21% in 2023. Horizon Databook has segmented the Latin America upstream bioprocessing market based on bioreactors/fermenters, cell culture products, filters, bioreactors accessories, bags & containers covering the revenue growth of each sub-segment from 2018 to 2030.
Latin America's upstream bioprocessing market is expected to be driven by the expansion of biopharmaceutical industry. Patent expirations provide numerous opportunities for development and commercialization of biosimilar products in this region. Latin American nations are exhibiting continuous progress in the establishment and development of clear regulations for biosimilars & other biopharmaceutical products.
Brazil and Mexico have established regulations based on local requirements & international standards. Chile, Panama, Argentina, Costa Rica, Guatemala, and Peru follow guidelines laid down by WHO and EMA.
As a result, some biopharmaceutical companies have commercialized around 170 biopharmaceuticals and biosimilars of etanercept and rituximab in this region. This is anticipated to boost bioprocessing procedures, thus increasing the region’s revenue generation over the forecast period.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America upstream bioprocessing market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America upstream bioprocessing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account